New Zealand markets closed

Edwards Lifesciences Corporation (EW)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
84.74+0.57 (+0.68%)
At close: 04:00PM EDT
84.50 -0.24 (-0.28%)
After hours: 07:22PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 52.53B
Enterprise value 51.70B
Trailing P/E 36.68
Forward P/E 31.06
PEG ratio (5-yr expected) 2.59
Price/sales (ttm)9.97
Price/book (mrq)8.84
Enterprise value/revenue 9.65
Enterprise value/EBITDA 26.98

Trading information

Stock price history

Beta (5Y monthly) 1.14
52-week change 3-27.62%
S&P500 52-week change 3-16.88%
52-week high 3131.73
52-week low 382.92
50-day moving average 397.31
200-day moving average 3106.14

Share statistics

Avg vol (3-month) 32.55M
Avg vol (10-day) 32.89M
Shares outstanding 5619.94M
Implied shares outstanding 6N/A
Float 8614.33M
% held by insiders 10.81%
% held by institutions 185.11%
Shares short (30 Aug 2022) 43.68M
Short ratio (30 Aug 2022) 41.59
Short % of float (30 Aug 2022) 40.60%
Short % of shares outstanding (30 Aug 2022) 40.59%
Shares short (prior month 28 Jul 2022) 45.54M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 23:1
Last split date 331 May 2020

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Jun 2022


Profit margin 27.18%
Operating margin (ttm)30.75%

Management effectiveness

Return on assets (ttm)12.80%
Return on equity (ttm)26.28%

Income statement

Revenue (ttm)5.35B
Revenue per share (ttm)8.60
Quarterly revenue growth (yoy)-0.20%
Gross profit (ttm)3.98B
Net income avi to common (ttm)1.46B
Diluted EPS (ttm)2.33
Quarterly earnings growth (yoy)-17.00%

Balance sheet

Total cash (mrq)1.52B
Total cash per share (mrq)2.44
Total debt (mrq)682.8M
Total debt/equity (mrq)11.49
Current ratio (mrq)3.37
Book value per share (mrq)9.59

Cash flow statement

Operating cash flow (ttm)1.53B
Levered free cash flow (ttm)1.1B